Category Archives: Biotechnology

There is an increasing focus on science being linked to providing practical solutions to agricultural problems. There is also increasing awareness of technology, although the channels used for information and creating change in the way information is passed and understood by the receiver are poorly developed. Biotechnology is no longer a new technology in Africa; some countries in Africa have adopted the technology, while some other countries are currently conducting confined field trial for the technology. In Nigeria, Genetically Modified Organisms (GMOs) which is a component of biotechnology is currently undergoing confined field trial in various locations. It is expected that in the next three years, the commercialisation of the BT cotton will commence in the country. Africa as a continent in the recent past have suffered a high level of food insecurity following the actions and inaction of various governments to put sustainable policies to fast track agricultural development. Some countries in Africa have also experienced food shortage due to some natural disaster which includes flood, pest attack, insect infestation and drought. In some countries, the uses of manual and outdated method of farming have contributed immensely to the countrys dependence for food supply on some developed countries that … Continue reading →

Cellect Biotechnology Kfar Saba, Israel-based Cellect Biotechnology Ltd's stock finished Monday's session 2.84% lower at $8.56 with a total trading volume of 27,234 shares. Over the previous three months and since the start of this year, the Company's shares have advanced 34.80% and 177.02%, respectively. The stock is trading above its 200-day moving average by 53.25%. Moreover, shares of Cellect Biotech, which focuses on developing solutions for immune system regeneration in Israel, have a Relative Strength Index (RSI) of 34.93. On May 23rd, 2017, Cellect Biotech announced that David Braun, Head of Merck Group's Medical Device Business, is joining the Company's Scientific and Medical Advisory Board. Mr. Braun has held multiple additional senior-level executive positions at leading biotech and high-tech companies, ranging from global Fortune 500 corporations to growth-oriented organizations, including Biosafe S.A., a stem cell separation leader recently acquired by GE, Newell Brands, Logitech, Chiaro Networks, and Elbit Systems. Your complete research report on APOP can be retrieved for free at: http://dailystocktracker.com/registration/?symbol=APOP BioDelivery Sciences Shares in Raleigh, North Carolina headquartered BioDelivery Sciences International Inc. declined 4.26%, ending yesterday's session at $2.25 with a total trading volume of 405,472 shares. The stock has gained 25.00% in the past month, 9.76% … Continue reading →

Forests are under many threats, from new pests and pathogens, to invasive trees, to climate. The advancement of these traits by far exceeds the natural response of trees to acclimate, and outpaces the efforts to traditionally breed trees for forest conservation and restoration. Dr. Ellen V. Crocker is a postdoctoral researcher at the University of Kentucky. She talks about the current threats to forests including sudden oak death, chestnut blight and the emerald ash borer. She also discusses efforts in integrating new biotech tools in forest improvement, including genetic engineering, speed breeding, and gene drive approaches. Hosted by Dr. Paul Vincelli (@Pvincell). Follow Dr. Crocker on Twitter@evcrocker Follow Talking Biotech on Twitter@TalkingBiotech FollowKevin Folta on Twitter @kevinfolta|Facebook:Facebook.com/kmfolta/| Lab website:Arabidopsisthaliana.com| All funding: Kevinfolta.com/transparency Stitcher| iTunes|Player FM|TuneIn Visit Kevin Foltas Talking Biotech Go here to see the original: Talking Biotech: Can biotechnology help protect forests from pests ... - Genetic Literacy Project … Continue reading →

Puma Biotechnology (NYSE:PBYI) presents at ASCO thepositive results from an ongoing Phase II clinical trial of Puma's investigational drug PB272 for the treatment of HER2-positive metastatic breast cancer that has metastasized to the brain. The multicenter Phase II clinical trial enrolled patients with HER2-positive metastatic breast cancer who have brain metastases. The trial is being performed by the TBCRC and enrolled three cohorts of patients. We are very pleased with the activity seen in this trial with the combination of neratinib plus capecitabine, sys Puma CEOAlan Auerbach. As a small molecule that can cross the blood brain barrier, neratinib potentially offers patients with HER2-positive metastatic breast cancer that has metastasized to the CNS a novel HER2 targeted treatment option. We look forward to working with TBCRC on future trials of neratinib in patients with HER2-positive disease metastatic to the CNS," he adds. Source: Press Release #ASCO Excerpt from: Puma Biotechnology announces positive trial results - Seeking Alpha … Continue reading →

A post-secondary program in biotechnology opens doors to various careers in clinical research, DNA analysis, quality control and assurance, industrial microbiology and biochemistry, biology instrumentation and calibration. The graduates of this program demonstrate the ability to Isolate, enumerate and identify microorganisms Collect and store samples Prepare specimen for staining Prepare microbiological media and reagents and culture pathogenic microbes Design and perform microbiology experiments Sample, measure, collect and analyze data Calibrate and use laboratory instruments Apply appropriate safety procedures Handle hazardous chemicals The professionals can find employment in food, pharmaceutical and cosmetic industries as biotechnology technicians, lab technicians, biology lab assistants, life science lab technicians and instrumentation and calibration assistants. They can also work with companies into clinical research, quality testing and biotechnology product development. Choosing a Biotechnology College in Canada How you start your career depends on where you have studied, to a great extent. The biotechnology programs that have met the national technology accreditation requirements established by the Canadian Council of Technicians and Technologists (CCTT) and the Canadian Technology Accreditation Board (CTAB) offer better placement opportunities. It is important to ask the following questions before enrolling into a biotechnology college or course in Canada: Is the program accredited by … Continue reading →

Investorplace.com iShares NASDAQ Biotechnology Index (IBB) Downgraded by Vetr Inc. to "Hold" The Cerbat Gem iShares NASDAQ Biotechnology Index logo iShares NASDAQ Biotechnology Index (NASDAQ:IBB) was downgraded by equities research analysts at Vetr from a buy rating to a hold rating in a report issued on Monday. They presently have a $307.00 target ... Trade of the Day: iShares Nasdaq Biotechnology Index (ETF) (IBB)Investorplace.com iShares NASDAQ Biotechnology Index (IBB) Given News Impact Score of 0.10Sports Perspectives First Personal Financial Services Lowers Position in iShares NASDAQ Biotechnology Index (IBB)BBNS Chaffey Breeze -Stock Observer -BNB Daily (blog) all 73 news articles » See original here: iShares NASDAQ Biotechnology Index (IBB) Downgraded by Vetr Inc. to "Hold" - The Cerbat Gem … Continue reading →

A Toronto Stock Exchange (TSX) logo is seen in Toronto November 9, 2007. (Mark Blinch / Reuters) A Toronto Stock Exchange (TSX) logo is seen in Toronto November 9, 2007. (Mark Blinch / Reuters) Subscribers Only Sean Silcoff OTTAWAThe Globe and Mail Published Sunday, Jun. 04, 2017 3:36PM EDT Last updated Sunday, Jun. 04, 2017 3:39PM EDT The Canadian biotechnology business is a picture of good health. On Friday, management of Vancouver-based cancer therapy developer Zymeworks Inc. rang the bell on the Toronto Stock Exchange, five weeks after its stock debuted in a $59-million (U.S.) initial public offering in Canada and on the New York Stock Exchange. It was by far the largest biotech IPO on a Canadian exchange in a decade and came on the heels of one of the largest stock offerings ever by a Canadian biotech firm, after dual-listed lupus-drug developer Aurinia Pharmaceuticals Inc. raised $150.5-million in March. To continue reading this article, you must be a Globe Unlimited subscriber. Subscribe to Globe Unlimited now! Follow Sean Silcoff on Twitter: @SeanSilcoff Trudeau says Ottawa wont legalize illicit drugs other than marijuana (The Canadian Press) Discover content from The Globe and Mail that you might otherwise not have … Continue reading →

Biotechnology Technicians (also known as bench technicians) have the distinct job of assuring quality control in areas of manufacturing such as food, pharmaceuticals and cosmetics. These areas in which humans consume or use products are very important and require the utmost attention. Therefore, biotechnology technicians must attend a biotechnology college program before entering the field. If the field sounds like one in which you may have interest, Centennial College in Toronto, Ont. offers a two year Biotechnology Technician Industrial Microbiology program. Students are provided with thorough practical training in industrial microbiology as well as chemistry (analytical and organic) and biochemistry. As with all Centennial College programs, there are prerequisites to attending. First, students must present at minimum an Ontario Secondary School Diploma (OSSD) or equivalent or be 19 years of age or older. Also required is completion of compulsory English 12C or U or skills assessment, or equivalent and Math 11M or U or 12C or U or skills assessment, or equivalent. Students are placed in appropriate English level based on skills assessment results. Lastly, students who test at an advanced level may be accelerated directly into MATH-176 in semester 1 and MATH-186 in semester 2. Those taking MATH-140 will … Continue reading →

Science has multiple wings and streams and studying one of them and specializing in it can open up various career prospects for the candidates. A couple of such streams that are gaining importance and popularity are biotechnology and microbiology. Both are integral parts of biological science and both have their respective uses. Pursuing a graduation or masters degree in the field may prove extremely rewarding for the users. Many students these days are pursuing the BSc Biotechnology and higher degrees in search of building up their career graph. Understanding Biotechnology Biotechnology involves the use of genetic as well as biochemical processes related to the living organisms for using them for humans. There are numerous genetically modified crops in the field of agriculture and there are also multiple genetically modified vaccines in the field of healthcare and medications. In some of the leading science colleges in Dehradun particular emphasis is given to the application of the principles of biotechnology in DNA applications and cell regulation in human anatomy. While the BSc degrees offered by these colleges include basic applications in the field the MSc Biotechnology degree offers higher levels of use of the biochemical processes and their impact studies. Work Placement … Continue reading →

LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology, Inc. (Nasdaq: PBYI), a biopharmaceutical company, announced the presentation of positive results from an ongoing Phase II clinical trial (Translational Breast Cancer Research Consortium TBCRC 022) of Puma's investigational drug PB272 (neratinib) for the treatment of HER2-positive metastatic breast cancer that has metastasized to the brain. The data were presented today in an oral presentation at the American Society of Clinical Oncology (ASCO) 2017 Annual Meeting in Chicago, Illinois. The multicenter Phase II clinical trial enrolled patients with HER2-positive metastatic breast cancer who have brain metastases. The trial is being performed by the TBCRC and enrolled three cohorts of patients. Patients in the first cohort (n=40) included those with progressive brain metastases who were administered neratinib monotherapy. Data from this cohort were previously reported at the 2014 ASCO Annual Meeting and published in the Journal of Clinical Oncology in 2016. Patients in the second cohort (n=5) represent patients who had brain metastases which were amenable to surgery and who were administered neratinib monotherapy prior to and after surgical resection. The third cohort (target enrollment=60) enrolled two sub-groups of patients (prior lapatinib-treated and no prior lapatinib) with progressive brain metastases who were administered neratinib in combination with … Continue reading →